GUANGZHOU,China,March 7,2025-- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO","MINISO Group" or the "Company"),a global value retailer offering a variety
03-10
BEIJING,March 5,2025-- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN),China\'s leading used car retailer,today announced that,it entered into certain definitive agreements w
03-06
WUHAN,China,March 5,2025-- A report fromChangjiang Daily. This is Wuhan: a journey through time Recently,"Traveling in China" has become a highly trending topic on social media platforms,as
03-06
HONG KONG,March 6,2025-- Akeso,Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical tria
03-06
SHANGHAI,March 4,2025-- USHOPAL Group continues to solidify its position as the first China-based luxury beauty group to emerge on the global stage,with an acquisition strategy that focuses on strong
03-06
BARCELONA,Spain,March 5,2025-- GTS Techlabs,the technology arm ofGlobe Teleservices (GTS),a leading telecom solutioncompany,and Peacom have announced a strategic partnership at Mobile World Congress
03-06
Revenue grew 93.5% to $10.5 million in the fourth quarter and 40.9% year-over-year to $30.6 million in 2024
03-06
BARCELONA,Spain,March 5,2025-- At MWC Barcelona 2025,the Broadband Development Congress (BDC),hosted by the WBBA,was a resounding success. Themed "Smarter Broadband: Investment. Innovation. Intel
03-06
PhaseIb trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL),aiming to reshape the standard-of-care landscape.
03-06
HONG KONG,March 6,2025-- Akeso,Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical tria
03-06
CGTN: How China embraces the world with open arms, boosts development for all
Cangxi County Holds 2026 New Year's Cultural Performance for the Public
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
©copyright 2009-2020 Singapore Info Map
